MAP2K7 and hepatocellular carcinoma: Treatment outcomes for NRAS-mutated and NRAS-wild type patients were investigated in 2 retrospective trials for MEK inhibitor and/or immune checkpoint inhibitors showing modest improvement.46,47 Thus, these 5 genes identified in this study might help to select the systemic treatment for HCC patients.